Bartlett HIV/AIDS Review: September 15, 2004 Dr. Bartlett reviews the latest data on TDF vs d4T, FTC vs d4T, EFV vs ATZ, hyperlactatemia after NRTI switch, HAART and sexual risk-taking, cancer risk ...

From the identification of HIV as the agent that causes AIDS, to the development of effective antiretroviral drugs, the scientific achievements in HIV research in the past 20 years have been ...

The conference emphasized advancements in HIV pathogenesis, persistence, and gene therapy, alongside policy and drug use intersections. Lenacapavir was found safe in adolescents, offering new insights ...

The human immunodeficiency virus (HIV) has stubbornly stated that it is here to stay, causing the devastating HIV/AIDS epidemic. Fortunately, human stubbornness and resilience are not in short supply ...

In the study published in the journal Emerging Microbes and Infections, the team demonstrated that the patented therapeutic candidate, an HIV-virus-like-particle (HLP), is 100 times more effective ...

In a first, the study published in the journal Emerging Microbes and Infections demonstrated the team’s patented therapeutic candidate, an HIV-virus-like-particle (HLP), is 100 times more effective ...

We might be a step closer to curing HIV, as researchers have developed a way to knock out a version of the virus lurking in the body. Using something called an HIV-like particle (HLP)—which are dead ...

The autophagy process, a critical regulator of T-cell function, has been shown to control acute HIV-1 infection and play a crucial role also in HIV-1 disease pathogenesis. Moreover, previous studies ...

In a first, the study published in the journal Emerging Microbes and Infections demonstrated the team's patented therapeutic candidate, an HIV-virus-like-particle (HLP), is 100 times more effective ...

The immune system remains seriously out-of-whack—in an inflammatory state of overactivation and impaired functionality—following the international gold standard for treating people with latent ...